Core Points - PwC announced that Sichuan Ruijian Medical's financial statements are set to expire on December 31, 2024, leading the company to voluntarily apply for a suspension of its subsequent listing review process on September 26, 2025 [1] - As of the announcement date, the review status for the subsequent listing has been adjusted to suspended by the Beijing Stock Exchange [1] - On September 30, 2025, Sichuan Ruijian Medical received a second round inquiry letter regarding its application for public stock issuance and listing on the Beijing Stock Exchange [1] - The subsequent listing and its review process have not been terminated, and related matters are still ongoing, resulting in the company's shares being suspended on the National Equities Exchange and Quotations system [1] - The company will issue further announcements in accordance with listing rules as necessary [1]
普华和顺(01358.HK)：四川睿健医疗将于全国中小企业股份转让系统继续停牌